This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Hotflush | |
|---|---|
| Name | Hotflush |
| Specialty | Endocrinology, Gynecology |
| Symptoms | Sudden warmth, flushing, sweating, palpitations |
| Onset | Perimenopause, medication changes |
| Duration | Seconds to minutes |
| Frequency | Intermittent |
| Causes | Hormonal fluctuation, pharmacologic agents |
| Risks | Smoking, obesity, surgical menopause |
| Diagnosis | Clinical, ambulatory monitoring |
| Treatment | Lifestyle modification, pharmacotherapy, hormone therapy |
Hotflush
A hotflush is an acute sensation of intense warmth often accompanied by visible flushing, sweating, and autonomic symptoms occurring in diverse clinical contexts such as menopause, endocrine disorders, oncologic therapy, and iatrogenic drug effects. It is a symptom encountered across specialties including Endocrinology, Gynecology, Oncology, Cardiology, and Psychiatry and is evaluated with reference to conditions such as the Climacteric, Thyroid storm, Carcinoid syndrome, and adverse effects of agents like Tamoxifen, Opioids, and Selective serotonin reuptake inhibitors.
The term denotes a transient vasomotor episode characterized by cutaneous vasodilation, increased skin temperature, and sudomotor activation. In clinical literature it is variably termed "hot flash" in North American sources and appears in diagnostic discussions alongside entities like Vasomotor symptoms of menopause, Autonomic dysfunction, and terminology in manuals such as the International Classification of Diseases for coding related presentations. Distinctions are made between physiologic hotflushes linked to the Menopause transition and pathologic episodes in conditions like Pheochromocytoma or during treatment with agents referenced in guidelines from bodies such as the American College of Obstetricians and Gynecologists.
Hotflushes arise from dysregulation of thermoregulatory centers in the Hypothalamus and altered neurotransmitter signaling involving pathways modulated by Estrogen, Serotonin, Norepinephrine, and peptides such as Calcitonin gene-related peptide. Common etiologies include the decline in ovarian function during the Menopausal transition, abrupt estrogen withdrawal after procedures like Bilateral oophorectomy, and endocrine tumors including Carcinoid tumor or Pheochromocytoma. Pharmacologic precipitants include endocrine therapies for Breast cancer such as Aromatase inhibitors, central nervous system agents like Dopamine agonists, and vasoactive drugs used in Cardiology and Psychiatry. Systemic illnesses such as Hyperthyroidism and infections documented in Infectious disease literature can provoke similar vasomotor responses through inflammatory mediators and altered metabolic rate.
Clinically, patients report sudden heat spreading to the face, neck, and chest, often with erythema, perspiration, palpitations, anxiety, and sometimes chills during resolution. Differential diagnosis requires exclusion of cardiac ischemia, autonomic neuropathy seen in Diabetes mellitus, and paroxysmal events like those in Panic disorder or manifestations of Carcinoid syndrome. Diagnostic evaluation leverages history, focused examination, and targeted testing: measurement of serum Thyroid-stimulating hormone, sex steroids, and urinary catecholamines or 5-HIAA when tumor is suspected; ambulatory skin conductance monitoring and core temperature assessment are used in specialized centers and trials endorsed by authorities such as the National Institutes of Health. Scales developed in trials by groups affiliated with institutions like Mayo Clinic and Johns Hopkins Hospital quantify frequency and severity for research and management.
First-line measures emphasize lifestyle interventions recommended by organizations including World Health Organization guidance on tobacco cessation and weight reduction, clothing and environmental adaptations, and cognitive approaches from Cognitive behavioral therapy literature. Pharmacologic options with evidence from randomized trials include systemic Hormone replacement therapy for eligible postmenopausal patients, centrally acting agents such as Selective serotonin reuptake inhibitors (e.g., Paroxetine), Serotonin-norepinephrine reuptake inhibitors (e.g., Venlafaxine), and gabapentinoids referenced in neuropathic pain and vasomotor symptom studies. For cancer survivors, nonhormonal strategies are favored to avoid interactions with treatments like Tamoxifen or Aromatase inhibitor therapy according to guidance from organizations such as ASCO. Interventional approaches — including stellate ganglion block — have been explored in case series originating from tertiary centers like Cleveland Clinic.
Hotflushes are highly prevalent; population studies from cohorts such as the Women's Health Initiative and the Study of Women's Health Across the Nation report rates varying by age, ethnicity, and menopausal stage. Peak incidence occurs in the perimenopausal years, with persistence for months to years in many individuals; surgical menopause and bilateral oophorectomy are associated with earlier and more severe onset, as described in surgical series from centers like Mayo Clinic. Modifiable risk factors include obesity, smoking, and alcohol use, while comorbidities such as Type 2 diabetes mellitus and prior chemotherapy exposure for malignancies like Breast cancer increase likelihood and severity. Cultural and geographic differences documented in multinational surveys involve cohorts from Europe, North America, and Asia.
While typically benign, frequent or severe episodes impair sleep, mood, and quality of life and are linked to increased absenteeism and healthcare utilization documented in health services research from institutions like Kaiser Permanente and National Health Service (England). Long-standing vasomotor symptoms correlate with depressive symptoms and sexual dysfunction described in psychosexual studies from Kings College London and University College London. Prognosis is generally favorable with targeted therapy: many patients achieve substantial symptom reduction with hormone therapy or nonhormonal pharmacotherapy, and multidisciplinary management pathways advocated by societies such as the Endocrine Society and International Menopause Society optimize long-term outcomes.
Category:Menopause Category:Endocrinology